期刊文献+

吡格列酮联合瑞格列奈治疗2型糖尿病的疗效分析 被引量:5

下载PDF
导出
摘要 目的观察吡格列酮联合瑞格列奈治疗2型糖尿病的疗效及其对胰岛素抵抗和肾功能的影响。方法选取2型糖尿病患者210例,随机分为观察组和对照组,每组各105例,对照组予以瑞格列奈治疗,观察组在对照组的基础上予以吡格列酮治疗。观察2组治疗前后空腹(FBG)、糖化血红蛋白(HbA1c)、空腹胰岛素(FINS),胰岛素抵抗指数(HOMA-IR)、尿素氮(BUN)、肌酐(Cr)和血尿酸变化。结果治疗后,2组血浆中的FBG和HbA1c水平均较治疗前明显降低(P<0.01),而观察组的降低水平较对照组更为明显(P<0.05或0.01)。治疗后,观察组的血浆FINS、HOMA-IR、BUN、尿酸和Cr水平均较治疗前和对照组明显降低,2组比较有显著性差异(P<0.01)。结论吡格列酮联合瑞格列奈治疗2型糖尿病疗效显著,对胰岛素抵抗具有改善作用,安全性好。
作者 王珏 王维杰
出处 《现代中西医结合杂志》 CAS 2013年第8期840-841,共2页 Modern Journal of Integrated Traditional Chinese and Western Medicine
  • 相关文献

参考文献10

  • 1Chang YH, Chang DM , Lin KC,et al. Visfatin in overweight/obesi-ty ,type 2 diabetes mellitus, insulin resistance, metabolic syndromeand cardiovascular diseases : a meta-analysis and systemic review[J]. Diabetes Metab Res Rev,2011,27(6) :515 -527.
  • 2Reyes-Soffer G,Rondon-Clavo C ,Ginsberg HN. Combination thera-py with statin and fibrate in patients with dyslipidemia associatedwith insulin resistance,metabolic syndrome and type 2 diabetesmellitus[ J]. Expert Opin Phannacother,2011,12(9) : 1429 - 1438.
  • 3Pappa KI,Gazouli M,Economou K,et al. Gestational diabetes mel-litus shares polymorphisms of genes associated with insulin resist-ance and type 2 diabetes in the Greek population [ J ]. Gynecol En-docrinol,2011,27 (4) :267 -272.
  • 4Gatenby VK,Kearney MT. The role of IGF - 1 resistance in obesityand type 2 diabetes-mellitus-related insulin resistance and vasculardisease[ J]. Expert Opin Ther Targets,2010,14(12) : 1333 - 1342.
  • 5Jorge ML,de Oliveira VN,Resende NM,et al. The effects of aero-bic ,resistance,and combined exercise on metabolic control, in-flammatory markers,adipocytokines,and muscle insulin signalingin patients with type 2 diabetes mellitus [ J ]. Metabolism,2011,60(9):1244 -1252.
  • 6Mehta NN,Krishnamoorthy P,Martin SS,et al. Usefulness of insulinresistance estimation and the metabolic syndrome in predicting coro-nary atherosclerosis in type 2 diabetes mellitus[ J]. Am J Cardiol,2011,107(3) :406 -411.
  • 7Serlie MJ,Allick G,Groener JE,et al. Chronic treatment with piogl-itazone does not protect obese patients with diabetes mellitus type IIfrom free fatty acid-induced insulin resistance [ J ]. J Clin Endocri-nol Metab,2007 ,92(1) :166 -171.
  • 8Namvaran F, Rahimi-Moghaddam P, Azarpira N , et al. Polymorph-ism of adiponectin (45T/G) and adiponectin receptor -2 ( 795G/A) in an Iranian population: relation with insulin resistance and re-sponse to treatment with pioglitazone in patients with type 2 diabetesmellitus[ J]. Mol Biol Rep,2012,39(5) :5511 - 5518.
  • 9Stephens J W,Bodvarsdottir T B , Wareham K,et al. Effects of short-term therapy with glibenclamide and repaglinide on incretin hor-mones and oxidative damage associated with postprandial hypergly-caemia in people with type 2 diabetes mellitus [ J ]. Diabetes ResClin Pract,2011,94(2) :199 -206.
  • 10胡菊萍,陶冬青,张令晖.吡格列酮联用瑞格列奈治疗2型糖尿病的疗效[J].中国药师,2009,12(11):1594-1595. 被引量:6

二级参考文献3

  • 1Spiegelman BM. PPARγ adipogenic regulator and thiazolidinedione receptor [J]. Diabetes ,1998,47 (4) :507-514.
  • 2Kofod H, Fuhlendorff J. Effect of repaglinide on insuhn release in isolated islets of langerhans is unaffected by metabolic stress induced by chnitrophenol [ J ]. Eur J Endocrinol , 1995,132 : 14.
  • 3陈家伦.第四讲:噻唑烷二酮类治疗2型糖尿病的疗效及安全性[J].中华内分泌代谢杂志,2000,16(4):268-269. 被引量:48

共引文献5

同被引文献28

引证文献5

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部